Although c-kit + cardiac progenitor cells (CPCs) are currently used in clinical trials there remain considerable gaps in our understanding of the molecular mechanisms underlying their proliferation and differentiation. G-protein coupled receptors (GPCRs) play an important role in regulating these processes in mammalian cell types thus we assessed GPCR mRNA expression in c-kit + cells isolated from adult mouse hearts. Our data provide the first comprehensive overview of the distribution of this fundamental class of cardiac receptors in CPCs and reveal notable distinctions from that of adult cardiomyocytes. We focused on GPCRs that couple to RhoA activation in particular those for sphingosine-1-phosphate (S1P). The S1P 2 and S1P 3 receptors are the most abundant S1P receptor subtypes in mouse and human CPCs while cardiomyocytes express predominantly S1P 1 receptors. Treatment of CPCs with S1P, as with thrombin and serum, increased proliferation through a pathway requiring RhoA signaling, as evidenced by significant attenuation when Rho was inhibited by treatment with C3 toxin. Further analysis demonstrated that both S1P-and serum-induced proliferation are regulated through the S1P 2 and S1P 3 receptor subtypes which couple to Gα 12/13 to elicit RhoA activation. The transcriptional co-activator MRTF-A was activated by S1P as assessed by its nuclear accumulation and induction of a RhoA/MRTF-A luciferase reporter. In addition S1P treatment increased expression of cardiac lineage markers Mef2C and GATA4 and the smooth muscle marker GATA6 through activation of MRTF-A. In conclusion, we delineate an S1P-regulated signaling pathway in CPCs that introduces the possibility of targeting S1P 2/3 receptors, Gα 12/13 or RhoA to influence the proliferation and commitment of c-kit + CPCs and improve the response of the myocardium following injury.
Introduction
The heart was traditionally thought to be a terminally differentiated post-mitotic organ incapable of cardiac myocyte regeneration. However the accumulation of experimental evidence, including the occurrence of natural cardiomyocyte apoptosis [1, 2] , telomere shortening of cardiomyocytes [3, 4] , and histological images of myocyte replication [5] changed the perception of the heart to a dynamic self-renewing organ that has the potential of undergoing cardiomyocyte turnover. Endogenous multipotent cardiac progenitor cells (CPCs), positive for the stem cell lineage marker c-kit and negative for hematopoietic markers, were discovered in the adult mammalian heart, including the mouse, rat and human [6] [7] [8] . In addition, these endogenous CPCs have been observed to respond to cardiac injury in vivo [8] . In mouse models, ckit + CPCs were shown to undergo population expansion along the border zones of the infarct region following myocardial infarction (MI) [8] .
Although these endogenous CPCs exist and localize in areas of damaged myocardium, very little is known about the molecular mechanisms that regulate their biology, or why they fail to spontaneously regenerate cardiac tissue in the diseased heart. Sphingosine-1-phosphate (S1P), a sphingolipid metabolite, is a bioactive signaling molecule that binds to specific G-protein coupled receptors (GPCRs) and has been implicated in regulating cellular processes such as maintenance of pluripotency, differentiation, proliferation, survival, and migration in a wide variety of cell types including stem cells [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . The release of S1P from the mouse heart is increased following myocardial infarction and ischemia/reperfusion (I/R) [20, 21] serving to acutely protect the heart against ischemic injury [20, [22] [23] [24] [25] [26] . In addition S1P acts as a chemoattractant for hematopoietic stem cells following MI [27] . The effect of S1P on the endogenous c-kit + CPCs has not, (Gα i , Gα q/11 , Gα s , and Gα 12/13 ) but the S1PR 1 subtype is limited in coupling only to Gα i [31] . The S1P 2 and S1P 3 receptors which, in contrast to S1PR 1 , couple to both the Gα q and Gα 12/13 proteins are effective activators of the low molecular weight G-protein RhoA [32, 33] . We have attributed the cardioprotective effect of S1P in the mouse heart following I/R to activation of S1P 2 and S1P 3 receptors [22] and more recently to activation of RhoA [25] . RhoA activation promotes actin polymerization, a response originally associated with altered contractile function but subsequently shown to also result in the accumulation of myocardin-related transcription factor A (MRTF-A) in the nucleus [34] [35] [36] [37] [38] . MRTF-A is a transcriptional co-activator which binds to serum response factor (SRF) to induce gene transcription [39] [40] [41] [42] . The activation of MRTF-A in mesenchymal stem cells (MSCs) had been shown to play a role in MSC-mediated angiogenesis and induce MSC differentiation into several cell types, including endothelial and contractile smooth muscle cells [43] [44] [45] . Studies using MRTF-A knockdown implicate it in myotube formation and SRF-dependent activation of muscle genes in vitro [41] and overexpression of MRTF-A in bone marrow stem cells has been shown to be protective following myocardial infarction in rats (MI) [46] . In the present study we assess the possibility that the predominance of S1PR 2/3 on CPCs might allow them to be targeted for expansion without affecting cardiomyocyte physiology through S1PR 1 activation. In particular given the unique ability of S1PR 2/3 receptor subtypes to couple to and signal through RhoA, we investigated the involvement of this signaling pathway in responses of c-kit + CPCs to S1P. We establish that S1P activates the Gα 12/13 coupled S1P 2 and S1P 3 receptors to elicit RhoA activation, and that this pathway leads to increased proliferation and MRTF-A regulated cardiac gene transcription.
Materials and methods

Animals
All procedures were performed in accordance with NIH Guide for the Care and Use of Laboratory Animals and approved by the Institutional Animal Care and Use Committee at the University of California San Diego. Male 8-12 week old FVB/N, C57BL/6J, S1PR 2 and-S1PR 3 -KO mice (kindly provided by Dr. Jerold Chun) were used for the isolation of c-kit + cardiac progenitor cells.
Cardiac c-kit + cell isolation
Adult c-kit + cardiac progenitor cells (CPCs) were isolated from 8 to 12 week old FVB/N, C57BL/6J WT, S1PR 2 -and S1PR 3 -KO mice as previously described [7] with modification. Briefly, mice were euthanized with CO 2 followed by cervical dislocation. The heart was cannulated on a Langendorff apparatus and perfused with warmed basic buffer followed by digestion with collagenase II solution. All buffers were made as described by Beltrami et al. The cell suspension was passed through a 30-micron filter (Miltenyi Biotec, Bergisch Gladbach, Germany) and incubated with CD117-conjugated Miltenyi magnetic microbeads to sort for c-kit + cells. Mouse cells were grown in Growth Medium, which consisted of Dulbecco's Modified Eagle's Medium and Ham's F12 (ratio 1:1), basic fibroblast growth factor (10 ng/ml), epidermal growth factor (20 ng/ml), leukemia inhibitory factor (10 ng/ml), embryonic stem cell fetal bovine serum (20%), and insulin-transferrin-selenite. Medium was changed 5-7 days later and the adherent cells were passaged using standard trypsinization protocols. For each isolation, the purity of the CPC population was assessed by FACs analysis at early passages. The typical % of c-kit + cells was 60-80%, while endothelial (CD31) and hematopoietic (CD45 and CD34) markers were present on the surface of less than 5-10% of the cell population. IDT TaqMan probes for human and mouse S1PR 1 , S1PR 2 , and S1PR 3 were used.
Transfections in CPCs
CPCs were transfected with siRNA or cDNA using DharmaFECT-1 transfection reagent (Thermo Scientific) based on the manufacturer's instruction and as previously described [25] . siRNA or cDNA and DharmaFECT-1 (in a 1:3 ratio, respectively) were individually incubated in Opti-MEM media (GIBCO) at room temperature for 5 min, mixed and incubated at room temperature for 20 min. The siRNA or cDNA/ DharmaFECT-1 mixtures (1 ml/dish) were added to cultures in Opti-MEM (GIBCO). After 4 h the cells were washed and fresh Growth Media added overnight.
For gene knockdown, predesigned mouse On-Targetplus siRNA for S1P 1 , S1P 2 , and S1P 3 receptors, RhoA, Gα 12 , Gα 13 , Gα i, Gα q , and MRTF-A was purchased from Thermo Scientific. All siRNAs had a knockdown efficiency of~80-100% when transfected 1 μg/well. In particular, the double knockdown of siGα 12 together with siGα 13 had an efficiency of~80% for both G proteins, while the single knockdown of one had no effect on the other isoform.
For cardiac lineage gene expression analysis upon MRTF-A overexpression, CPCs were transfected with 500 ng of a cDNA construct encoding MRTF-A, serum starved for 24 h and harvested 48 h later.
For luciferase assay, CPCs were plated on 12 well tissue culture plates (12,000 cells/well) in Growth Media. The following day, cells were transfected with an SRE.L reporter (500 ng) as well as a Renilla plasmid (50 ng) to normalize the luminescence signal.
After transfections, cells were starved for 24 h and either proliferation, qPCR, or luciferase assay was performed as described in Sections 2.5, 2.6 and 2.7 respectively.
Proliferation assay
To measure cell growth, CPCs were subjected to a CyQUANT NF Cell Proliferation Assay (Invitrogen, C35011). CPCs were plated on a transparent 48 well plate (8000 cells/well), cultured overnight with Growth Media and then maintained in serum free media for 24 h. CPCs isolated from FVB/N and used for most studies were stimulated with S1P (3 μM), thrombin (0.5 U/ml), lysophosphatidic acid (LPA, 10 μM) or serum (20%) for 24 h. CPCs from S1PR 2 -and S1PR 3 -KOs in a C57BL/6J background were stimulated with serum (20%) for 24, 48 and 72 h. For inhibition of Rho, cells were pretreated with C3 toxin (1 μg/ml) for 6 h prior to the addition of agonist. For knockdown of S1P receptors, cells were transfected as described in Section 2.4. Following stimulation, the plates were assayed according to the manufacturer's protocol and the fluorescence intensity determined using a Tecan Spectrophotometer as previously described [48] . 
Cardiac and smooth muscle lineage marker expression
Luciferase assay
CPCs were transfected with SRE.L and Renilla as described in Section 2.4. Following 24 h starvation, cells were treated with S1P (3 μM) or serum (20%) for 6 h. In the case of inhibition of Rho with C3-toxin (1 μg/ml), cells were pretreated for 6 h prior to agonist stimulation. For knockdown of G-proteins cells were transfected as described in Section 2.4.
Reporter activity was measured using the Promega Dual-Luciferase Reporter Assay based on the manufacturer's protocol.
Immunocytochemistry
CPCs were plated on 6-well tissue culture plates (10,000 cells/well) in Growth Media and serum starved the following day for 24 h. Cells were treated with S1P (3 μM) or serum (20%) in the presence or absence of C3-toxin (1 μg/ml) for 30 min, fixed in 4% paraformaldehyde, permeabilized with 10% Triton X-100, and incubated over-night with MRTF-A antibody 1:200 (Santa Cruz Biotechnology, sc-32909). The following day, cells were washed and incubated with the secondary antibody, Alexa-fluor 488 dye (Thermo Fisher Scientific) for 1 h. After washing, the slides were mounted with Vectashield with DAPI (Vector Laboratories) and analyzed using a Leica SP5 confocal microscopy (40× oil immersion objective). Images were acquired at a focal distance of 0.49 μm and z-stacks were compressed to provide a composite image (ImageJ software analysis, plugins Bio-format). Images from independent experiments were analyzed and the percentage of cells with nuclear MRTF-A localization was calculated for each (10 fields/experiment).
Statistical analyses
Researchers were blinded to the treatment group during analyses. Data are represented as mean ± SEM. Differences of p b 0.05 were considered statistically significant and were assessed using unpaired Student's t-test (for two groups), one-way (for multiple comparisons) or two-way (for multiple comparisons with more than one variable) ANOVA with post-hoc Tukey analysis using GraphPad Prism software (GraphPad, La Jolla, CA, USA).
Results
GPCR profiling in CPCs
To determine the complement of GPCRs present on c-kit + cardiac progenitor cells (CPCs) we analyzed the levels of mRNA in undifferentiated mouse CPCs via a TaqMan GPCR array. Over 200 GPCRs were expressed at levels 2 times higher than GAPDH and those most commonly studied for their roles in cardiac function are shown in Fig. S .I.1A. Interestingly, the relative expression of receptor subtypes in CPCs was different from that of cardiomyocytes for several GPCRs. Of interest, the expression of sphingosine-1 phosphate (S1P) receptor isoforms in CPCs differed from that reported for cardiomyocytes [29, 30] , as confirmed by qPCR analysis. Specifically whereas S1PR 1 is the predominant Fig. 1 . Expression of S1PR subtypes in adult cardiomyocytes, and in mouse and human cardiac progenitor cells. S1P receptor mRNA levels were analyzed by qPCR and expressed as fold versus GAPDH. (A) Cardiomyocytes (CMs) were isolated from adult mouse heart as described [28] and cardiac progenitor cells (CPCs) (B) mouse and (C) human isolated as described in the Materials and methods section. S1PR 1 was the highest receptor in CMs while S1PR 2 and S1PR 3 were the highest in mouse and human CPCs respectively. n = 4 in A, n = 5 in B, n = 1 in C.
receptor subtype in mouse cardiomyocytes (Fig. 1A) , S1PR 2 and S1PR 3 are the more highly expressed subtypes in mouse and human CPCs ( Fig. 1B and C) . S1PR 4 and S1PR 5 were not detected in mouse CPCs.
Since the CPCs we isolate and study are undifferentiated we also examined the expression of S1P receptor isoforms following treatment with dexamethasone, an intervention routinely used to induce differentiation and expression of cardiac lineage markers in CPCs [50] . Although S1PR 1 , S1PR 2 and S1PR 3 mRNA levels were increased, we did not observe a switch in the predominance of S1PR isoforms (Fig. S.I .1B) to resemble that of differentiated adult cardiomyocytes. This finding is consistent with other evidence that CPCs do not fully differentiate into functional cardiomyocytes in culture. We also noted that mRNAs for LPAR 1 and LPAR 2 subtypes, and for the thrombin receptor PAR1, all of which can activate RhoA [51] [52] [53] , were highly expressed in mouse CPCs (Fig. S.I.1A ).
3.2. The GPCR agonist S1P induces CPC proliferation in a RhoA dependent manner S1P, LPA, and thrombin have been shown to promote proliferation of various types of stem cells [11] [12] [13] [14] [15] [16] [17] [18] [19] . Thus, we asked if treatment with these agonists increased CPC proliferation and whether this occurred in a RhoA-dependent manner. CPCs cultured in serum-free medium and stimulated with S1P, thrombin ( Fig. 2A) or LPA (Fig. S.I .2) for 24 h showed a significant increase in proliferation (2.2, 1.8 and 3.2 fold respectively). As a control we utilized 20% serum, which increased proliferation 4 fold. In order to determine if the agonist-stimulated proliferation was RhoA-dependent, we pretreated CPCs with the C3 exoenzyme which ribosylates and functionally inactivates Rho. Thrombin and S1P-induced proliferation were significantly inhibited by C3 treatment and notably serum-induced proliferation was also fully inhibited ( Fig. 2A) . In contrast, the proliferative response to LPA was not blocked by C3 but was inhibited by treatment with pertussis toxin (Fig. S.I. 2), indicating that it is mediated through Gα i signaling. Strikingly serum-induced proliferation was fully inhibited by C3 but not pertussis toxin (Fig. 2A, Fig. S.I.2) suggesting that the S1P, thrombin or other ligands that activate RhoA are components of serum responsible for serum-induced proliferation.
To further elucidate the role of S1P receptor signaling on CPC proliferation we isolated c-kit + CPCs from S1PR 2 and S1PR 3 knockout (KO) mice (S1PR 1 deletion is embryonic lethal) and treated them with 20% serum. There was a significantly lower rate of serum-induced proliferation in CPCs from either S1PR 2 or S1PR 3 KOs compared to those from wild-type (WT) mice (Fig. 2B ). In addition, we used siRNA-mediated knockdown of all three S1P receptor subtypes in wild type CPCs (knockdown~80-90% for each) to examine the receptor subtypes through which S1P induces proliferation. S1P-induced proliferation was inhibited by knockdown of S1PR 2 or S1PR 3 , while knockdown of S1PR 1 did not affect S1P-induced proliferation (Fig. 2C) . Taken together these results suggest that S1P, alone or as a component of serum, promotes CPC proliferation through activation of S1P receptor subtypes that couple to RhoA.
RhoA dependent activation of MRTF-A by S1P in CPCs
Activation of RhoA in mesenchymal stem cells regulates SRF dependent gene transcription through its co-transcriptional activator, MRTF-A [43] . MRTF-A is also involved in transcriptional activation downstream of RhoA in other cell types [39] [40] [41] . We asked whether MRTF-A was activated downstream of S1P-induced RhoA signaling in CPCs. MRTF-A activation was assessed using immunofluorescence to examine increases in its nuclear accumulation. The percent of WT CPCs with nuclear MRTF-A staining increased significantly with S1P or serum treatment (Figs. 3A, B and 4A, B) . In CPCs from S1PR 2 or S1PR 3 KO mice MRTF-A nuclear accumulation was partially diminished in response to S1P (Fig. 3A  and B) . Furthermore inhibition of Rho by pre-treatment with C3 toxin Fig. 2 . S1P induced proliferation in CPCs is RhoA dependent and mediated through S1PR 2 and S1PR 3 . (A) Serum starved mouse CPCs were stimulated with S1P (3 μM), thrombin (0.5 U/ml) or 20% serum for 24 h and proliferation was measured using the CyQUANT assay. Pre-treatment with C3 toxin (1 μg/ml) blocked proliferation induced by S1P (3 μM), thrombin and serum.
# p ≤ 0.05 vs. control, *p ≤ 0.05 vs. treated by one-way ANOVA; n = 15, 7 independent experiments. (B) Serum starved CPCs isolated from WT, S1PR 2 KO and S1PR 3 KO mice stimulated with 20% serum. Proliferation was significantly lower in S1PR 2 or S1PR 3 KO CPCs than in WT. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.005 vs. WT by two-way ANOVA; n = 6, 3 independent experiments. (C) CPCs were transfected with control, S1P 1 , S1P 2 or S1P 3 receptor siRNA for 48 h prior to addition of S1P (3 μM) for 24 h. Knockdown of S1P receptor mRNA assessed by qPCR was~80-90% for all three receptor subtypes (data not shown). *p ≤ 0.05 vs. S1P treated control (siCTL) by oneway ANOVA; n = 4, 2 independent experiments. attenuated the nuclear accumulation of MRTF-A elicited by S1P and notably also that induced by serum ( Fig. 4A and B) . These findings demonstrate that S1P activates MRTF-A in CPCs through S1PR 2 and S1PR 3 and in a Rho-dependent mechanism.
S1P induces SRF-dependent transcriptional activity in CPCs
The accumulation of MRTF-A in the nucleus should lead to increased SRF-dependent transcriptional activity. To demonstrate that this occurs, and as further evidence of RhoA activation, we measured MRTF-A/SRF regulated activation of an SRE.L luciferase reporter gene in CPCs. As demonstrated in Fig. 5A , SRE.L luciferase activity was increased following 6 h of S1P or serum stimulation and both responses were abolished by pre-treatment with C3 toxin or by siRNA mediated knockdown of RhoA (data not shown). We also tested G-protein involvement and observed that S1P-induced SRE.L activity was significantly diminished by knockdown of Gα 12 and Gα 13 , but not of Gα q or Gα i (knockdown~80-100% for all G proteins) (Fig. 5B) . These findings demonstrate that S1P induces SRF-dependent transcriptional activation in CPCs through a RhoA/MRTF-A mediated signaling pathway and imply that Gα 12 and Gα 13 are both required.
S1P upregulates cardiac lineage markers through a RhoA/MRTF-A dependent pathway
Understanding the signaling pathways that regulate the expression of genes important for differentiation could enable use of the innate capacity of c-kit + CPCs to repair the heart. Since it is known that SRF/ MRTF-A plays a fundamental role in myogenesis [41, 42] , we asked whether S1P affects the expression of known cardiac or smooth muscle lineage marker genes. The extent of gene regulation by S1P was compared to that induced by dexamethasone. CPCs isolated from FVBN WT mice were treated with S1P or Dex in the absence of serum and harvested after 3 days. The mRNA levels of two cardiomyocyte markers (GATA4 and Mef2C) and a smooth muscle cell marker (GATA6) were analyzed by qPCR. As shown in Fig. S.I.3 , treatment of CPCs with S1P increased mRNA for GATA4 (~2 fold), Mef2C and GATA6 (both~3 fold). Cells cultured for 3 days under the same culture conditions but in the absence of S1P or Dex did not show significant increases in gene expression relative to time zero (data not shown). S1P induced increases in gene expression (Fig. 6A and B) were nearly equivalent to those of Dex (S.I. Fig. 3) . Notably, induction of these genes by S1P was significantly attenuated by the addition of a pharmacological inhibitor of MRTF-A activation, CCG-293971 [49] or by silencing MRTF-A through siRNA-mediated knockdown (~90% knockdown) ( Fig. 6A and B) . Furthermore we determined that overexpression of MRTF-A was sufficient to induce GATA4, Mef2C and GATA6 gene expression in CPCs (Fig. 6C) . This transcriptional response to MRTF-A was not attributable to changes in cell density since neither MRTF-A overexpression nor its inhibition affected CPC proliferation (data not shown). To determine the contribution of S1PR 2 or S1PR 3 to S1P induced cardiac gene changes in CPCs, we analyzed mRNA levels in CPCs isolated from C57Bl/6 WT, S1PR 2 and S1PR 3 KO mice treated with S1P. We confirmed that cardiac lineage marker genes were upregulated by S1P in the C57Bl/6 background as it was in FVBN. Genetic deletion of S1PR 3 significantly reduced S1P induced Mef2C and GATA4, while S1PR 2 deletion tended towards inhibition of GATA4 only (Fig. 6D) . Taken together our data demonstrate that prolonged treatment of CPCs with S1P stimulates the expression of cardiac lineage markers through activation of an S1PR/RhoA/SRF/ MRTF-A signaling pathway.
Discussion
During cardiac injury the heart attempts to maintain its ability to pump blood throughout the body. The persistence of the insult leads, however, to cardiac remodeling resulting from cardiomyocyte (CM) apoptosis and fibroblast proliferation, and this ultimately leads to cardiac dysfunction and death. In contrast to skeletal muscle where stem cells, called satellite cells, reside in the tissue and are activated upon injury to regenerate muscle [54] , the mammalian heart is incapable of spontaneous regeneration. On the other hand it has become evident in the last decade that adult c-kit + cardiac progenitor cells (CPCs) are present in the heart [55] and that exogenous delivery of these cells has salutary effect on cardiac performance. In fact, CPCs are currently being used in clinical trials for the treatment of heart failure in the SCIPIO (stem cell infusion in patients with ischemic cardiomyopathy) trial with striking results [56, 57] supporting the need to elucidate the signaling pathways influencing CPC function. Ideally the endogenous c-kit + cells would be utilized to repair the heart, thus recent work has considered means of enhancing their innate ability to proliferate, migrate and differentiate both in vitro and in vivo [58] [59] [60] [61] . In this context, our research has focused on identifying GPCR signaling pathways that regulate CPC function and which could be modulated or engaged in response to external stimuli or ligands. G-protein coupled receptors (GPCRs) are one of the largest known classes of receptors and highly drugable targets. Delineating the complement of GPCRs on CPCs and determining how their agonists affect CPC function could provide insights into ways to alter their function. The GPCRs present on CPCs have not been previously screened, and we determined here that the mRNA for more than 200 GPCRs are expressed in mouse c-kit + CPCs. Notably the relative expression levels of some physiologically important GPCR subtypes in the CPCs are distinct from those reported for CMs. For example, in contrast with the well-known higher abundance of the β 1 versus the β 2 adrenergic receptor (βARs) in CMs [62] , β 2 AR mRNA was more abundant in CPCs. The functional significance of the βAR subtype differences in CPCs and adult CMs was evidenced by the demonstration that β 2 AR receptor stimulation plays a role in protecting CPCs which is lost following a shift to β 1 AR during differentiation [63] . Similarly, the angiotensin iI (AT) receptor subtypes AT1 and AT2 show different relative expression levels with AT1 expressed at higher levels in adult cardiomyocytes [64] , whereas AT2 is predominant on c-kit + CPCs. Notably c-kit + AT2 receptor containing cells in the rat heart have been shown to increase after acute ischemic injury and to contribute to cardioprotection [65] . The fact that βARs and ATRs are important drug targets in heart failure (HF) and that the mechanisms by which β-blockers exert beneficial effects in the clinical treatment of HF are not fully understood suggests that the effects of these drugs on endogenous CPCs merits consideration; the potentially maladaptive changes in βAR and ATR subtypes during differentiation towards CMs could be a factor limiting CPCmediated cardiac healing. Signaling through and shifts in S1P receptor expression could likewise affect the cardiac response to injury. Accordingly, our work focused on the sphingosine-1 phosphate (S1P) receptors and in particular the unique role played by S1PR 2 and S1PR 3 in CPCs. We and others have shown that S1P plays a protective role against damage caused by ischemia/reperfusion (I/R) in the heart [20, 22, 26, 66] . Ex vivo studies have shown that perfusing the mouse heart with S1P either prior to or post ischemia reduces the infarct area when compared to untreated hearts [20, 25] . Our lab previously attributed the protective effects of S1P to S1PR 2 and S1PR 3 activation in studies comparing in vivo I/R injury in WT versus S1PR 2 and S1PR 3 knockout mice [22] . Mice lacking both S1PR 2 and S1PR 3 had an increase in infarct area relative to WT mice, implying that endogenous S1P released during MI serves a cardioprotective role through S1PR 2 and S1PR 3 signaling in the adult heart. This data is of particular interest considering that S1PR 2 and S1PR 3 are highly expressed in CPCs isolated from both mouse and human hearts and that these receptors mediate the effects of S1P and at least in part the effect of serum on CPC proliferation. Thus the predominance of S1P 2 and S1P 3 receptors may be important for enhancing CPC expansion. This has also been suggested to be the case in other stem cells, as in skeletal muscle, where S1P has been shown to be a key regulator in satellite cell biology, promoting cell proliferation and migration [67] [68] [69] . In particular S1PR 2 has been shown to promote muscle regeneration [70] and together with S1PR 3 has been implicated in the transmission of S1P-induced cell proliferation in satellite cells [67] , in line with our findings in CPCs.
While increasing proliferation of CPCs is critical to their participation in cardiac repair, the ability of these cells to regulate genes necessary for commitment or for paracrine signaling could further enhance their utility. Thus we investigated the effects of S1P on gene expression and involvement of RhoA, which is known to activate several downstream transcriptional regulators including the transcriptional co-activator MRTF-A. MRTF-A, together with myocardin and MRTF-B, is a member of a family of co-activators that regulates gene expression by their interaction with the transcription factor SRF [71] . Of note, while myocardin is constitutively localized in the nucleus, MRTF-A and -B associate with Gactin in the cytoplasm and translocate to the nucleus to activate SRF upon RhoA-dependent actin polymerization [71] . MRTF-A and B are thus responsible for transduction of the RhoA/actin signals to gene transcription. We demonstrate here that in S1P-treated CPCs, MRTF-A accumulates in the nucleus, and that this is dependent on both S1PR 2 and S1PR 3 . This nuclear accumulation is blocked by C3-toxin, supporting its dependence on Rho signaling. This is concordant with our finding that the SRF-dependent transcriptional activity induced by S1P in CPCs is dependent on Gα 12/13 , which couples to RhoA activation, but not on either Gα i , or Gα q . Thus while LPA elicits CPC proliferation through Gα i , and it has been reported that Gα i mediates ERK activation in response to S1P in embryonic stem cells [10] , the predominant S1P signaling pathway for both proliferation and gene expression of CPCs is through coupling of the more highly expressed S1P 2 and S1P 3 receptors to Gα 12/13 and RhoA.
MRTF-A has been shown to regulate genes involved in muscle cell differentiation, cardiovascular development, and epithelial-mesenchymal transition [40, 43, 44, 72] . MRTF-A has also been shown to induce the expression of SRF-dependent genes involved in smooth muscle cell differentiation [72] , and in undifferentiated embryonic stem cells overexpression of MRTF-A induces expression of genes encoding markers of SMC differentiation [73] . Similarly, a sphingosine metabolite, sphingosylphosphorylcholine (SPC), was shown to induce differentiation of mesenchymal stem cells into contractile smooth muscle cells through RhoA/Rho kinase-dependent nuclear translocation of MRTF-A [44] . In agreement with the role of Rho/MRTF-A in smooth muscle differentiation, we found that S1P was able to induce the expression of GATA6 in CPCs; in addition we demonstrated the effects on cardiac lineage markers Mef2C and GATA4. In this regard the response to S1P was similar to the well-described response of CPCs to dexamethasone. The transcriptional effect of S1P was dependent on the activation of MRTF-A, as evidenced by either MRTF-A gene silencing or pharmacological inhibition. Not only was MRTF-A necessary for S1P induced gene transcription but it was sufficient to induce cardiac lineage genes when transiently over-expressed in CPCs. The finding that genetic deletion of S1PR 2 or S1PR 3 only partially diminished S1P induced gene expression in CPCs is likely due to the redundant function of these receptors as mediators of RhoA activation [74] , and is supported by the fact that, neither of the S1PR KOs completely abolished MRTF-A nuclear accumulation. The low level of MRTF-A that still accumulates in the nucleus when either receptor is deleted may be sufficient for the induction of GATA6 explaining why it is not reduced.
In summary, the present study demonstrates for the first time that S1P increases proliferation and gene expression of CPCs, and that this occurs by activating S1PR 2/3 coupling to Gα 12/13 and RhoA and subsequently to SRF/MRTF-A dependent transcriptional response. The finding that S1P regulates CPC gene transcription through a MRTF-A dependent mechanism may have implications not only for lineage commitment but also additionally for regulation of genes and gene products that provide a more permissive environment for CPCs or other cells in the heart. For example, we and others have reported that S1P-dependent RhoA and MRTF-A activation in cardiomyocytes leads to the expression and subsequent secretion of the matricellular protein CCN1, a protein that mediates angiogenesis and cell survival [75, 76] . In addition recent work showed a functional role for RhoA and MRTF-A activation in regulating integrin expression in mesenchymal stem cells [45] . Future studies will attempt to identify factors that are regulated through S1P/RhoA/ MRTF-A signaling in CPCs and could influence not only their function and survival but also that of surrounding cells in the heart.
Conclusion
There is general agreement that the endogenous population of CPCs is, at the present, unable to repair the heart following injury. However, we have delineated a signaling cascade through which an endogenous GPCR agonist, S1P can enhance CPC proliferation and gene expression. A better understanding of the genes and processes regulated by S1P, a ligand generated by the heart following injury, should inform future approaches to enhance the therapeutic potential of CPCs.
Supplementary data to this article can be found online at http://dx. doi.org/10.1016/j.cellsig.2016.04.006.
